News

The Phase 1 trial will evaluate single and multiple ascending doses of oral BCX9250 in healthy volunteers. The company expects to report the results from the trial in

Cosentyx, which is an inhibitor of interleukin-17A (IL-17A), could not show statistical significance for superiority in ACR 20 over the AbbVie drug in the head-to-head late-stage trial. As

BeiGene is a research-based, oncology-focused biotechnology company with an established and highly experienced team in China, including a 700-person commercial organization and a 600-person clinical development organization. “This

The study is the first in the strategic oncology partnership announced between Daiichi Sankyo and Sarah Cannon, designed to expedite and optimize global clinical development of Daiichi Sankyo’s

This agreement covers four products in rare metabolic and neurological disorders and each product will utilise Catalent’s Zydis® oral disintegrating tablet (ODT) and Zydis Ultra® technologies. Zydis technology

Under the research collaboration and licensing agreement, the companies will work on the worldwide development and commercialisation of DCR-HBVS, Dicerna’s investigational therapy in phase 1 clinical development for

The collaboration will see the modular biologics and functional immunology expertise of Pandion combined with the advanced therapeutics development and global commercialisation capabilities of Astellas for the treatment

Validation confirms that the submission is complete and signifies the MAA is under review by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The U.S. Food

Rett syndrome is a serious and rare neurodevelopmental congenital CNS disorder with symptoms that typically present between six to 18 months of age, and lead to problems with